Mergers & Acquisitions ·
Supernus Pharmaceuticals delists from Nasdaq following completion of merger on November 2
SUPNSupernus, Inc.
Supernus Pharmaceuticals, Inc. notified Nasdaq of the completion of a merger on November 2, 2026, and requested the suspension of trading for its common stock effective prior to market open. The company filed Form 25 with the SEC to effect the delisting from Nasdaq and deregistration under Section 12(b) of the Securities Exchange Act. Supernus intends to file Form 15 to suspend reporting obligations under Sections 13 and 15(d). As a result, its common stock will no longer be listed on any national securities exchange. The company operates in the pharmaceutical industry.